Showing Latest Articles
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
British Journal of Cancer, 09/01/2011
Exclusive author commentary
Zang RY et al. – This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.
RY Zang (09/02/2011) comments:
It is the first pooled analysis of secondary cytoreduction for relapsed platinum-sensitive ovarian cancer. We quantified the prognostic factors and established a model of survival, which will guide personalized patient selection for a secondary surgical effort or salvage chemotherapy. Further ongoing randomized trials will validate the prognostic factors and the risk model.